65,437 trials
Glabellar Frown Lines
Primary: Percentage of Participants With a ≥2 Point Improvement in Glabellar Line Scale (GLS) as Independently Assessed by Investigator and and Subject — 70.4; 1.3 percentage of…
Asthma
Primary: Treatment Failure — 6; 3 Participants — p=0.3
Heart Failure
Primary: Freedom From Left Ventricular Lead-Related Complications Through 3 Months — 96 percentage probability
Traveler's Diarrhea
Primary: Time to Last Unformed Stool (TLUS) — 44.3; 40.3 hours
Actinic Keratosis
Primary: Part 1: Number of Participants Experiencing a Dose Limiting Toxicity (DLT) Based on Local Skin Responses (LSRs) — 3; 3; 6; 6 Participants
Heart Failure, Congestive
Primary: Interstitial Volume (ve) in Heart Failure Participants and Healthy Volunteers at Baseline — 0.4946; 0.3346; 0.5078; 0.3253 Liter — p=0.0029
Overactive Bladder
Primary: Urinary Frequency — 10.5; 11; 12; 8.5 urinations
Cluster Headache
Primary: Comparison of the Headache Pain Free Attack Rates at 15 Minutes Following the Treatment — 495; 400; 67; 46 Number of attacks
Adult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLL
Primary: Number of Patients Achieving Complete Response Within 3 Months — 1; 1; 5; 0 Participants
Healthy
Primary: Part A: Number of Participants With an Injection Site Adverse Event — 3; 0 Participants
Phenylketonuria
Primary: Blood Phenylalanine Concentrations — 1382.7; 1336.1; 1290.5; 846.0 umol/L
Low Back Pain
Primary: Pain Intensity (Average) — 4.0; 5.7 score on a scale
White Spot Lesions
Primary: DIAGNOdent Readings at Baseline, Three and Six Months - Intergroup Comparison — 5.10; 6.01; 4.08; 5.50 units on a scale — p=0.636
Aortic Aneurysm, Thoracic
Primary: Composite Safety and Effectiveness Endpoint That is Based on the Percentage of Subjects Who Experienced (a) Access and/or Deployment Failures; and/or (b) Major Device…
Advanced Metastatic Breast Cancer
Primary: Progression Free Survival (PFS) by Investigator Assessment — 23.8; 13.0 Months — p=<0.0000001